About a third of all people with Crohn’s disease (CD) develop perianal fistulas. These are often difficult to treat and can have a major impact on quality of life, affecting physical and emotional wellbeing, social and professional life, educational activities and intimate relationships.
The only available tool for assessing the status of perianal fistulas and whether there is response to treatment is the Perianal Disease Activity Index (PDAI). The PDAI focuses on clinical targets and only briefly addresses quality of life; it was developed without input from patients living with the condition, and is completed by the clinician.
We aim to develop a new patient-centred quality of life assessment scale with the help of people living in the community with CD-related perianal fistulas with patients. We will call this the Crohn’s Anal Fistula Quality of Life scale (CAF-QoL). The CAF-QoL has the potential for widespread use in research, in development of new interventions, and in clinical practice where it will enable assessment of the effectiveness of fistula treatments and the impact of these on patients’ quality of life.
This study is a 3-phase study.
In this phase, phase 3 - we asked patients to complete the CAF-QoL on two separate occasions; to determine whether the CAF-QoL is stable over time (reliable).
Participation: For this study we recruited 115 volunteers from the IBD BioResource to complete the CAF-QoLe.
Organisation: This study is organised by Professor Ailsa Hart from St Mark's Hospital.
